Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H32O3 |
Molecular Weight | 356.4984 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]3([H])C4=C(CC[C@@]23[H])C=C(OC5CCCC5)C=C4
InChI
InChIKey=ODYKCPYPRCJXLY-PZORDLPLSA-N
InChI=1S/C23H32O3/c1-23-11-10-18-17-9-7-16(26-15-4-2-3-5-15)12-14(17)6-8-19(18)20(23)13-21(24)22(23)25/h7,9,12,15,18-22,24-25H,2-6,8,10-11,13H2,1H3/t18-,19-,20+,21-,22+,23+/m1/s1
Molecular Formula | C23H32O3 |
Molecular Weight | 356.4984 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Quinestradol is an estrogen derivative patented by Francesco Vismara Societa per Azioni and Alberto Ercol for the treatment of senile vulvovaginitis and related conditions. In preclinical trilals, quinestradol shows feminizing action in rats. A clinical trial of Quinestradol appeared to be justified since there was considerable evidence that the preparation was safe and free from side effects.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4890404
0.25 mg four times a day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:28:32 GMT 2023
by
admin
on
Fri Dec 15 16:28:32 GMT 2023
|
Record UNII |
422L8173W8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C483
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
422L8173W8
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
PRIMARY | |||
|
C012021
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
PRIMARY | |||
|
1778
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
PRIMARY | |||
|
DTXSID30878638
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
PRIMARY | |||
|
35215
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
PRIMARY | RxNorm | ||
|
2341
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107004
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
PRIMARY | |||
|
100000080295
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
PRIMARY | |||
|
C76999
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
PRIMARY | |||
|
Quinestradol
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
PRIMARY | |||
|
14626804
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
PRIMARY | |||
|
SUB10210MIG
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
PRIMARY | |||
|
214-623-2
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
PRIMARY | |||
|
m912
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
PRIMARY | Merck Index | ||
|
1169-79-5
Created by
admin on Fri Dec 15 16:28:32 GMT 2023 , Edited by admin on Fri Dec 15 16:28:32 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |